



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/816,673	04/02/2004	Fredrik Nicklasson	PC27889A	9702
28523 7590 06/20/2007 PFIZER INC. PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD GROTON, CT 06340			EXAMINER LEITH, PATRICIA A	
			ART UNIT 1655	PAPER NUMBER
			MAIL DATE 06/20/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<p align="center"><b>Office Action Summary</b></p>	<p><b>Application No.</b></p> <p>10/816,673</p>	<p><b>Applicant(s)</b></p> <p>NICKLASSON ET AL.</p>	
	<p><b>Examiner</b></p> <p>Patricia Leith</p>	<p><b>Art Unit</b></p> <p>1655</p>	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 21 March 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

## **DETAILED ACTION**

Claims 1-16 are pending in the application and were examined on their merits.

Previous rejections not re-stated below were removed due to Applicant's persuasive arguments.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-8 and 11-16 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-36 of U.S. Patent No. 6,517,864 B1 in view of Girsh (US 5,753,296).

Jacobsen et al. (US 6,517,864 B1) claims tolterodine R and S isomeric forms, as well as the tolterodine metabolite (R ) –N,N-diisopropyl-3-(20hydroxy-5-hydroxymethylphenyl)-3 phenylpropanamine in combination with topical carriers for oral, sublingual and buccal administration (see Claims 1-37). It is clear from the most recent response by Applicants that this patent was commonly owned at the time the Invention was made.

Jacobsen et al. did not suggest the incorporation of cocoa powder, a lipid such as cocoa butter, a sweetener or an emulsifier such as lecithin.

Girsh (US 5,753,296) taught chocolate compositions containing hypoallergenic cocoa powder which advantageously included pharmaceutical agents for sublingual/mucosal delivery (see entire reference especially col.2, lines 61-67, col. 14, lines 3-52). In a specific embodiment, Girsh prepares a 'High phosphatidylcholine lecithin, sugar-free, chocolate flavored aspirin' in Example XXVII (col. 28) which comprised aspirin, hypoallergenic cocoa powder, lecithin, vanilla, cocoa butter and maltitol, formed into small units to be "...utilized as a pleasant tasting, high mucosal penetrating and oral absorbable delivery system which is maintained sublingually in the mouth until completely dissolved".

Girsh specifically explains that

The inventive chocolate composition may be utilized as a vehicle for delivery of oral medications to **mask drug flavor** and provide for enhanced drug uptake via the oral mucosa. For example, a dosage form may be prepared by coating a medicament with a chocolate coating according to the present invention, or by mixing the medicament in a liquid or powder form with the chocolate composition. A chewable tablet, e.g., aspirin tablet, may thus be formed. The drug may comprise any pharmaceutical suitable for oral delivery, in particular those drugs

such as dihydroergotamine...which are difficult to deliver by the oral route on account of poor absorption... (see col. 14, lines 17-28 – emphasis added).

Although Girsh taught the use of *hypoallergenic* cocoa powder, it was cocoa powder none-the-less in the composition.

One of ordinary skill in the art would have been motivated to incorporate the composition of Jacobsen et al. in to a chocolate wafer as disclosed by Girsh in order to increase intraoral uptake of the tolterodine. Tolterodine was already a well-known pharmaceutical agent known for treating urinary problems. Further well-known were cocoa powder-containing compositions (i.e., 'chocolate tablets') for increasing transmucosal delivery of active ingredients. Therefore, the ordinary artisan would have had a reasonable expectation that the combination of the references would have been an advantageous means of incorporating tolterodine into a chocolate containing wafer which was suitable for buccal or sublingual delivery; especially considering that tolterodine was already known to be transmucosally available. Although Girsh specifically showed an example where aspirin was added into the chocolate-containing composition; it was clear from the Girsh reference that any pharmaceutical agent could have been used, as the object of the Girsh patent was to formulate a hypoallergenic chocolate-containing medicament for sublingual/buccal delivery of active agents.

Claims 1-16 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-36 of U.S. Patent No. 6,517,864 B1 in view of Girsh (US 5,753,296) in view of Pather et al. (US 6,200, 604 B1).

The teachings of Jacobsen et al. and Girsh were discussed *supra*. Neither reference specifically suggested the incorporation of a buffer such as sodium carbonate.

Pather et al. (US 6,200, 604 B1) disclosed the use of buffers such as sodium carbonate in order to formulate effervescent sublingually administered dosage forms (see Abstract). Specifically, Pather et al. explain that "One aspect of this invention is to use effervescent as penetration enhancers for influencing oral drug absorption. **Effervescent agents can be used alone** or in combination with other penetration enhancers, which leads to an increase in the rate and extent of absorption of an active drug. It is believed that such increase can rise from one or all of the following mechanisms:

(14) 1. reducing the mucosal layer thickness and/or viscosity;

(15) 2. tight junction alteration;

(16) 3. inducing a change in the cell membrane structure; and

(17) 4. increasing the hydrophobic environment within the cellular membrane" ( col. 2, lines 16-27, emphasis added).

Pather et al. specifically suggested the use of buffering agents such as sodium carbonate and bicarbonates as the effervescing agent (see, col. 2, lines 41-63).

One of ordinary skill in the art would have been motivated to add a buffer such as sodium carbonate or bicarbonates in order to impart an effervescing property to the sublingual dosage forms which would have advantageously increased the mucosal uptake of tolterodine.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made



Art Unit: 1655

to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-8 and 11-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobsen et al. (WO 00/12070) in view of Girsh (US 5,753,296).

Art Unit: 1655

Jacobsen et al. (WO 00/12070) taught a transmucosal delivery agent in combination with tolterodine for treating overactive bladder (see Abstract for example). Specifically, Jacobsen et al. claimed the tolterodine R and S isomeric forms, as well as the tolterodine metabolite (R ) –N,N-diisopropyl-3-(20hydroxy-5-hydroxymethylphenyl)-3 phenylpropanamine in combination with topical carriers for oral, sublingual and buccal administration (see Claims 1-37).

Jacobsen et al. did not suggest the incorporation of cocoa powder, a lipid such as cocoa butter, a sweetener or an emulsifier such as lecithin.

Girsh (US 5,753,296) taught chocolate compositions containing hypoallergenic cocoa powder which advantageously included pharmaceutical agents for sublingual/mucosal delivery (see entire reference especially col.2, lines 61-67, col. 14, lines 3-52). In a specific embodiment, Girsh prepares a 'High phosphatidylcholine lecithin, sugar-free, chocolate flavored aspirin' in Example XXVII (col. 28) which comprised aspirin, hypoallergenic cocoa powder, lecithin, vanilla, cocoa butter and maltitol, formed into small units to be "...utilized as a pleasant tasting, high mucosal penetrating and oral absorbable delivery system which is maintained sublingually in the mouth until completely dissolved".

Girsh specifically explains that

The inventive chocolate composition may be utilized as a vehicle for delivery of oral medications to **mask drug flavor** and provide for enhanced drug uptake via the oral mucosa. For example, a dosage form may be prepared by coating a medicament with a chocolate coating according to the present invention, or by mixing the medicament in a liquid or powder form with the chocolate composition. A chewable tablet, e.g., aspirin tablet, may thus be formed. The drug may comprise any pharmaceutical suitable for oral delivery, in particular those drugs such as dihydroergotamine...which are difficult to deliver by the oral route on account of poor absorption... (see col. 14, lines 17-28 – emphasis added).

Although Girsh taught the use of *hypoallergenic* cocoa powder, it was cocoa powder none-the-less in the composition.

One of ordinary skill in the art would have been motivated to incorporate the composition of Jacobsen et al. in to a chocolate wafer as disclosed by Girsh in order to increase intraoral uptake of the tolterodine. Tolterodine was already a well-known pharmaceutical agent known for treating urinary problems. Further well-known were cocoa powder-containing compositions (i.e., 'chocolate tablets') for increasing transmucosal delivery of active ingredients. Therefore, the ordinary artisan would have had a reasonable expectation that the combination of the references would have been an advantageous means of incorporating tolterodine into a chocolate containing wafer which was suitable for buccal or sublingual delivery; especially considering that

tolterodine was already known to be transmucosally available. Although Girsh specifically showed an example where aspirin was added into the chocolate-containing composition; it was clear from the Girsh reference that any pharmaceutical agent could have been used, as the object of the Girsh patent was to formulate a hypoallergenic chocolate-containing medicament for sublingual/buccal delivery of active agents.

Claims 1-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jacobsen et al. (WO 00/12070) in view of Girsh (US 5,753,296) in view of Pather et al. (US 6,200, 604 B1).

The teachings of Jacobsen et al. and Girsh were discussed *supra*. Neither reference specifically suggested the incorporation of a buffer such as sodium carbonate.

Pather et al. (US 6,200, 604 B1) disclosed the use of buffers such as sodium carbonate in order to formulate effervescent sublingually administered dosage forms (see Abstract). Specifically, Pather et al. explain that "One aspect of this invention is to use effervescent as penetration enhancers for influencing oral drug absorption.

**Effervescent agents can be used alone** or in combination with other penetration enhancers, which leads to an increase in the rate and extent of absorption of an active drug. It is believed that such increase can rise from one or all of the following mechanisms:

- (14) 1. reducing the mucosal layer thickness and/or viscosity;
- (15) 2. tight junction alteration;
- (16) 3. inducing a change in the cell membrane structure; and
- (17) 4. increasing the hydrophobic environment within the cellular membrane" ( col. 2, lines 16-27, emphasis added).

Pather et al. specifically suggested the use of buffering agents such as sodium carbonate and bicarbonates as the effervescent agent (see, col. 2, lines 41-63).

One of ordinary skill in the art would have been motivated to add a buffer such as sodium carbonate or bicarbonates in order to impart an effervescent property to the sublingual dosage forms which would have advantageously increased the mucosal uptake of tolterodine.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention because cocoa powder containing vehicles were known in the art for the preparations of sublingual/transmucosal delivery of active agents. Further known is that tolterodine was administered transmucosally; that is, sublingually and buccally. It is clear

Art Unit: 1655

from the prior art that substances such as lecithins, cocoa butter, oils such as soybean oil, sweeteners and flavoring agents are routinely added to confectionary-type carriers containing chocolate/cocoa powder and that these types of carriers enhanced intraoral uptake of pharmaceutical agents. It was also well known in the art that effervescing agents such as carbonates and bicarbonates increased transmucosal uptake of active ingredients. Further, the addition of known, conventional additives to the composition does not render the composition patentable, because as stated *supra*, these compounds were routinely used in chocolate containing compositions and do not appear to impart any unexpected results to the composition.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

No Claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia Leith whose telephone number is (571) 272-0968. The examiner can normally be reached on Monday - Friday 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Patricia Leith  
Primary Examiner  
Art Unit 1655

June 4, 2007

A handwritten signature in black ink, appearing to read 'Patricia Leith', with a large, stylized initial 'P' and a long, sweeping horizontal stroke extending to the right.